Company* | Funding | Amount | Type | Details (Date) |
| | ||||
3rd Millennium | Department | $0.75 | Phase II | To fund the development of a microarray information system to support infectious disease research in the U.S. Army Medical Research and Materiel Command (1/28) |
AGEN | Australian | A$1.98 (US$1.1) | START | To assist AGEN's development of ThromboView, a blood-clot diagnostic imaging project (3/19) |
Ansata | Families of SMA, Fights SMA/ Andrew's Buddies and the Hereditary Disease Foundation | ND | Research | For Ansata to apply its molecular transduction technology in several neurodegenerative disease-related translational research projects (4/14) |
Aphios Corp.* | National Institute | ND | Phase I | To develop anti-influenza agents by screening Aphios' library of marine molecule fractions for activity against influenza A and influenza B (1/8) |
Applied Genetic | National | $0.132 | SBIR | To provide funding to investigate changes in the company's adeno-associated viral vectors to target particular tissue types (1/24) |
AquaPharm | UK government | £0.05 ($0.079) | Grant | To develop AquaPharm's marine drug discovery program (3/5**) |
AuraZyme | National | $0.1 | Grant | For a feasibility study of CryoLife's AZ-Plasmin drug technology in treating blood clots (3/12) |
Avant Immuno- | National | $0.127 | Phase I | To support preclinical development of Ty800, a single-dose, oral typhoid vaccine (1/13) |
BioForce | National | ND | SBIR | To design and test microcantilever devices for the purpose of improving deposition of biomaterials in ultraminiaturized arrays (1/28) |
BioForce | National | $0.5 | SBIR | To build an antibody nanoarray for the creation of diagnostic tests requiring extremely small sample volumes, approaching that of a single cell (4/15) |
Blue Heron | National | $2.4 | Phase II | To accelerate Blue Heron's ongoing research in gene synthesis and enhance its GeneMaker automated gene synthesis platform (2/6) |
Cerylid | National | $2.2 | Grant | To progress into clinical development CBL316, a compound that was identified in the company's natural products library of 600,000 extracts (2/20) |
Combinix Inc.* | National Cancer | ND | SBIR | To discover red-shifted, long- wavelength fluorescent dyes for use as reporter molecules in high- throughput screening, fluorescent microscopy and optical imaging (1/29) |
Devgen NV* (Belgium) | The Flemish | €2.5 (US$2.5) | Technology development grant | To support Devgen's technology, based on industrialized C. elegans assays (1/9) |
Echelon | National | $0.5 | Research | To investigate and identify targets against cancer and diabetes, specifically molecules that function as antagonists of PI 3-kinase signaling (2/10) |
Elusys | National | $1.2 | Two-year | To support development of a drug to protect people at risk of serious complications from the smallpox vaccine (3/10) |
Genomatica | Defense Advanced Research Projects Agency | ND | SBIR | To develop in silico technology for drug toxicity prediction (1/7) |
Gen-Probe Inc. | National Heart, Lung, and Blood Institute | $2.47 | Contract | To continue development of a nucleic acid test for the detection of West Nile virus in donated blood and organs (3/25) |
Hollis-Eden Pharmaceuticals | Office of Naval | $0.43 | Preclinical research | For Roger Loria at Virginia Commonwealth University's Medical College of Virginia to study the effects of Hollis-Eden's immune- regulating hormone, HE2200, in the treatment of traumatic shock (2/3) |
Hybrigenics | French Ministry | €1.4 (US$1.48) | Grant | To finance the development of protein-protein interaction technology and bioinformatics tools designed for the GenHomme program (3/19**) |
Icogen Corp.* | National | $1 | SBIR | To fund a project to identify inhibitors of chemokine receptors that may be developed to treat inflammatory diseases (2/5) |
Kibow Biotech | National | ND | Phase I | For a project titled "A Dietary Supplement to Augment Kidney Function" (1/2) |
Kosan | National | $0.4 | Phase I | To develop a means of producing the polyketide laulimalide (3/11) |
Kosan | National | $0.75 | Phase II | To support research on developing generic hosts for polyketide overproduction, with a focus on hosts that produce antimicrobial polyketides (2/27) |
Marligen | U.S. government | ND | SBIR | To develop methods for studying transcription factors (1/10) |
Maxim | National | $0.75 | Phase II | To fund additional testing of MX2167, Maxim's apoptosis- inducing drug candidate for cancer (3/13) |
MitoKor | National Eye | ND | Phase I | To support MitoKor's program to develop and commercialize neuroprotective drugs for the prevention of disease progression in glaucoma (2/3) |
Molecular | National | $2.5 | Grant | To produce large samples of genomic DNA, which will be made widely available to the scientific community for on- going genetic disease studies (2/4) |
Neurochem | National | $1 | Research | To support Neurochem's Phase II trials of Cerebril for the prevention of recurrent hemorrhagic stroke due to cerebral amyloid angiopathy (1/30) |
NovaScreen | National | ND | Phase I | To develop a "Ligand Binding and Functional Assay-based HERG Database" (3/6) |
Oxford | UK government | €0.9 (US$0.97) | Development grant | To fund the development of 5T4, a tumor-associated antigen (2/19**) |
PBL | National | $1.38 | Grant | To enable the company to continue commercialization of one of its technology platforms; PBL is producing a next generation of interferon molecules called ultra interferons (1/14) |
Psimei | UK government | £0.45 (US$0.709) | Grant | To enable Psimei to progress its photon activation therapy for treating cancer into clinical trials (3/5**) |
Renovis | National | ND | Phase I | For development of target validation and drug candidate optimization technologies to be used in psychiatric drug development (2/12) |
Replicon | National | $0.472 | Phase II | To develop replicons as brain tumor therapies (1/28) |
Sunesis | National | ND | SBIR | For research to discovery anti-cancer therapeutics (1/30) |
Thales | Hungarian | ND | Small | To finance the development of a tool that integrates continuous of ComGenex Inc.; flow production with microfluidic processes in a single chip (1/29) |
Tranzyme | Institute for | $0.5 | Grant | To use the TranzVector gene delivery system to create neuronal cell lines expressing single or multiple Alzheimer's disease-related genes for use in high- throughput assays of beta-amyloid production (3/25) |
Vion | National | ND | Phase I | To evaluate protein expression with genomic and proteomic approaches in pairs of Salmonella with and without tumor growth inhibition activity (2/4) |
Virtual | National | ND | Phase I | To enable the exploration of new methodologies to produce cell arrays on Virtual Arrays' CellCard platform (3/18) |
XenoPort | National | $1.2 | Phase II | To support development of new methods for identifying transcytosis pathways and the discovery of ligands capable of engaging those pathways to improve the oral absorption of certain drugs (3/10) |
Zapaq Inc.* | Institute for | $0.25 | Follow-on | To develop drugs that inhibit a family of enzymes called aspartic proteases to treat Alzheimer's disease (1/22) |
TOTAL: $27.849M |
||||
| |
||||
Notes: |
||||
This chart does not include grants that are tied to agreements between biotech companies and nonprofit institutions. |
||||
* Indicates a privately held company or institution. |
||||
** Denotes the date the item ran in BioWorld International. |
||||
Unless otherwise indicated, symbols listed are on the Nasdaq market. |
||||
ND = Not disclosed; SBIR = Small Business Innovation Research |
||||
LSE = London Stock Exchange; NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange |
||||
